  Event of the same type occurring several times for one individual (recurrent
events) are present in various domains (industrial systems reliability,
episodes of unemployment, political conflicts, chronic diseases episodes).
Analysis of such kind of data should account for the whole recurrence process
dynamics rather than only focusing on the number of observed events.
Statistical models for recurrent events analysis are developed in the counting
process probabilistic framework. One of the often-used models is the
Andersen-Gill model, a generalization of the well-known Cox model for
durations, which assumes that the baseline intensity of the recurrence process
is time-dependent and is adjusted for covariates. For an individual i with
covariates Xi, the intensity is as follows: $\lambda$_{ik}(t;$\theta$) =
$\lambda$_0(t) exp (X_i $\beta$). The baseline intensity can be specified
parametrically, in a form of Weibull: $\lambda$_0 (t) = $\gamma$_{1}
$\gamma$_{2} t^{$\gamma$_2-1}, with $\gamma$1 scale parameter et $\gamma$2
shape parameter. However, the observed covariates are often insufficient to
explain the observed heterogeneity in data. This is often the case of clinical
trials data containing information on patients. In this article a mixture model
for recurrent events analysis is proposed. This model allows to account for
unobserved heterogeneity and to cluster individuals according to their
recurrence process. The intensity of the process is parametrically specified
within each class and depend on observed covariates. Thus, the intensity
becomes specific to class k: $\lambda$_{ik} (t; $\theta$_k) = $\gamma$_{1k}
$\gamma$_{2k} t^{$\gamma$_{2k}-1} exp (X_i $\beta$_k). The model parameters are
estimated by the Maximum Likelihood method, using the EM algorithm. The BIC
criterion is employed to choose the optimal number of classes. Model
feasibility is verified by Monte Carlo simulations. An application to real data
concerning hospital readmissions of elderly patients is proposed. The proposed
model feasibility is empirically verified (the optimization algorithm
converges, providing non-biased estimates). The real data application allows to
identify two clinically relevant classes of patients.
